MacroGenics, Inc. (MGNX) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear...
Analysis Summary
MacroGenics, Inc. reported revenue of $149.5M in the most recent fiscal year, growing at a 5-year CAGR of 8.9%.
Trailing-twelve-month margins: gross margin 50.4%, operating margin -24.3%, net margin -8.7%.
At the current price of $4.08, MGNX has negative trailing earnings (P/E not meaningful) and an ROE of -31.27%. Market capitalisation stands at $259M.
Balance sheet quality for MGNX: current ratio of 5.1, net cash position of $83.2M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $4.08 |
| Market Cap | $259M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 6.05 |
| EV / EBITDA | -2.46 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -31.27% |
| Return on Invested Capital | -2.36% |
| Return on Assets | -4.22% |
| Gross Margin | 50.44% |
| Operating Margin | -24.30% |
| Net Margin | -8.70% |
Financial Health
| Debt / Equity | 0.82 |
| Current Ratio | 2.96 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -6.01 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| MGNX | MacroGenics, Inc. | $259M | 6.05 | -31.3% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price Performance
| 1 month | -0.24% |
| 3 months | -1.21% |
| Year-to-date | +153.42% |
| 1 year | +166.67% |
| 3 years | -10.92% |
| 5 years | -80.08% |
52-Week Range
| 52-week High | $5.08 |
| 52-week Low | $1.29 |
| Avg Volume (90d) | 963K |
Related companies: CLNN · CNTB · CNTX · COYA · IFRX · ORMP · OVID
Explore sector: Healthcare · Biotechnology
More sections of MGNX: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks